Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986458 · 1 trial · 1 indication
Part B2 Cohort B only
| Arm | Type | Description |
|---|---|---|
| Part A1 | EXPERIMENTAL | Single Agent |
| Part A2 | EXPERIMENTAL | Combination Treatment |
| Part B1 | EXPERIMENTAL | Single Agent |
| Part B2 | EXPERIMENTAL | Combination Treatment |
| Part B3 | EXPERIMENTAL | Single Agent |
| Name | Type | Description |
|---|---|---|
| BMS-986458 | DRUG | Specified dose on specified days. |
| Rituximab | DRUG | Specified dose on specified days. |
| Glofitamab/Obinutuzumab | DRUG | Specified dose on specified days |
| Mosunetuzumab | DRUG | Specified dose on specified days |
| Epcoritamab | DRUG | Specified dose on specified days |
| Golcadomide | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants ≥ 18 years of age with frontline or R/R NHL. * Participant must have measurable disease (defined by at least one FDG-avid lesion for FDG-avid disease and one bi-dimensionally measurable disease on cross sectional imaging by computed tomography or magnetic resonanc...
BMS-986458 is an investigational small molecule being studied for the treatment of relapsed/refractory Non-Hodgkin Lymphoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
BMS-986458 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
BMS-986458 is in Phase 1 clinical development. It is an investigational drug being studied in a Phase 1 trial for relapsed/refractory Non-Hodgkin Lymphoma, and it has not yet received FDA approval.
BMS-986458 is being studied in a Phase 1 clinical trial with the identifier NCT06090539. This trial evaluates BMS-986458 alone and in combination with anti-lymphoma agents in patients with relapsed/refractory Non-Hodgkin Lymphoma, with an enrollment of 460 participants.
BMS-986458 is a small molecule therapeutic being developed for oncology. As a small molecule, it is designed to interact with cellular targets to exert its effects, though the specific molecular target has not been disclosed in available information.